This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

41/100

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Disease mechanisms

Topic: Brain proteins, microglia and lab models

Plain-language summary

Aggregation of the microtubule-binding protein tau is the histopathological hallmark of Alzheimer's disease (AD) and other neurodegenerative diseases, which are collectively known as tauopathies. Tau aggregation in AD patients is correlated with neuron loss, brain atrophy, and cognitive decline, and pro-aggregation tau mutations are sufficient to cause neurodegeneration and dementia in humans and tauopathy model mice. Thus, reversing tau aggregation is a potential therapeutic avenue for AD. In a previous study, we discovered CNS-11, a small molecule that disaggregates AD patient brain-extracted tau fibrils in vitro. In this study, we identify two chemical analogs of CNS-11, named CNS-11D and CNS-11G, that disaggregate AD patient brain-extracted tau fibrils and prevent seeding in a tau aggregation cell culture model. We also demonstrate that 8 weeks of treatment with either CNS-11D or CNS-11G reduces levels of insoluble tau in a mouse model of tauopathy. Our work defines the properties of two small molecules that diminish aggregation of tau in vivo and provides further support for structure-based methods to target tau for treatment of AD.

What this study adds

Evidence grade: Low

Two chemical analogs of CNS-11 disaggregated tau fibrils from Alzheimer's patient brains in the laboratory and reduced insoluble tau in a mouse model of tauopathy after 8 weeks of treatment. This is early laboratory and animal research, so it is not yet known whether these molecules would be safe or effective in people.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Pan, H., Cheng, X., Zhang, J., Hou, K., Murray, K. A., Manglani, K., et al. (2026). In Vitro and In Vivo Evaluation of Small-Molecule Disassemblers of Pathological Tau Fibrils. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00940

Vancouver

Pan H, Cheng X, Zhang J, Hou K, Murray KA, Manglani K, et al. In Vitro and In Vivo Evaluation of Small-Molecule Disassemblers of Pathological Tau Fibrils. ACS Chemical Neuroscience. 2026. doi:10.1021/acschemneuro.5c00940. PMID: 41486697.

BibTeX

@article{pan2026-41486697,
  author  = {Pan, Hope and Cheng, Xinyi and Zhang, Jeffrey and Hou, Ke and Murray, Kevin A. and Manglani, Kapil and Zhu, Cansheng and Hsu, Hung‐Kai and others},
  title   = {{In Vitro and In Vivo Evaluation of Small-Molecule Disassemblers of Pathological Tau Fibrils}},
  journal = {ACS Chemical Neuroscience},
  year    = {2026},
  doi     = {10.1021/acschemneuro.5c00940},
  pmid    = {41486697},
  url     = {https://doi.org/10.1021/acschemneuro.5c00940}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Thus, reversing tau aggregation is a potential therapeutic avenue for AD.
In a previous study, we discovered CNS-11, a small molecule that disaggregates AD patient brain-extracted tau fibrils in vitro.
In this study, we identify two chemical analogs of CNS-11, named CNS-11D and CNS-11G, that disaggregate AD patient brain-extracted tau fibrils and prevent seeding in a tau aggregation cell culture model.
We also demonstrate that 8 weeks of treatment with either CNS-11D or CNS-11G reduces levels of insoluble tau in a mouse model of tauopathy.
Our work defines the properties of two small molecules that diminish aggregation of tau in vivo and provides further support for structure-based methods to target tau for treatment of AD.

Why it matters

Study details

Evidence strengthLow

How this study scored 41/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (ACS Chemical Neuroscience)
Journal's citation record	1 / 4	ACS Chemical Neuroscience: journal h-index 124 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Laboratory or animal study (title names “in vitro”) — scores zero
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 3 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	1.5 citations a year over 2 year(s) since 2026
Impact for its field and year	4 / 6	Cited 12.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author David S Eisenberg: h-index 139 (OpenAlex, whole career)
Institution's track record	2 / 3	University of California, Los Angeles: institution h-index 1,923 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41486697)
Free to read	0 / 2	Behind a paywall — scores zero
Total	41 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.

Related studies in Disease mechanisms from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →